Latest From Biotech Now

NPR’s Shots Blog: Vaccine Fears Fueled The Resurgence Of Preventable Diseases

outbreaksvaccineLoop

This past weekend, Michaeleen Doucleff at NPR’s Shots blog shared a fascinating but disturbing map from the Council on Foreign Relations, How Vaccine Fears Fueled The Resurgence Of Preventable Diseases. The map covers 2008-2013 and shows outbreaks of measles, mumps, rubella, polio, whooping cough, and other diseases that are preventable with vaccines. As the article notes, we’ve seen a large increase in whooping cough cases here in the US. While the 24,000 cases seen in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Stable Policy Can Help Assure Unwavering Investment in U.S. Biofuels

Jim Greenwood

The Renewable Fuel Standard (RFS) is a unique federal policy that has, just as its bipartisan supporters intended, spurred major domestic and international investment in US biofuels production and it is essential to maintaining a growing market for second generation biofuels. That growing market helps attract investment to advanced biofuel companies who are trying to expand their infrastructure, scale up their production line, and improve their technology foundation. Unfortunately, the Environmental Protection Agency’s (EPA) recent Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO CEO Company Snapshot: Conatus Pharmaceuticals

Conatus-Pharma

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. What is your company’s lead product or technology? Conatus’s lead product is emricasan, a first-in-class oral Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Hill’s Congress Blog: Innovation in medicine isn’t optional – it’s imperative

TheHill

Earlier this week, The Hill’s Congress Blog posted an op-ed penned by Andrew von Eschenbach and Paul Howard entitled, “Innovation in medicine isn’t optional – it’s imperative” highlighting the importance of encouraging innovation and preserving incentives for drug development. The authors recommend increased cooperation and collaboration between industry, academia, and regulators, in addition to recognition by the federal government that ‘a vibrant life-sciences industry will generate higher national productivity, lower total health care costs, and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,